Study #2023-0685
A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors.
MD Anderson Study Status
Enrolling
Treatment Agent
Asciminib Pediatric formulation group, Asciminib Adult formulation group
Description
The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib from adult to pediatric patients will be conducted. Full extrapolation is based on the concept that CML in the pediatric population has the same pathogenesis, similar clinical characteristics and progression pattern as in adults.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myeloid Leukemia, Philadelphia Positive
Study phase:
Physician name:
David McCall
Department:
Pediatrics
For general questions about clinical trials:
1-833-992-0260
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.